Evidence map›Paper›PMID 42146678›Full record

ArticlebioRxiv : the preprint server for biology2026

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Jared Thompson, Kadin T Crosby, Hesong Han, Wayne Ngo, Chenglong Xia, Daniel Rosas-Rivera, Min Hyung Kang and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Jingkun ZengGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA, 94158.
Zhiyuan ChengGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA, 94158.
Huadong ChenHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Jared ThompsonDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.
Kadin T CrosbyDepartment of Chemistry and Biochemistry, Utah State University, Logan, UT, USA.
Hesong HanInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA, 94720.
Wayne NgoGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA, 94158.
Chenglong XiaInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA, 94720.
Daniel Rosas-RiveraGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA, 94158.
Min Hyung KangInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA, 94720.
Ying MaoHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Giselle LeeThe Francis Crick Institute, London, UK.
John F X DiffleyThe Francis Crick Institute, London, UK.
Yixuan SongThe Francis Crick Institute, London, UK.
Longhui QiuDepartment of Medicine, UCSF, San Francisco, California, USA.
Nathan M KrahDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.
Niren MurthyInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA, 94720.
Ryan N JacksonDepartment of Chemistry and Biochemistry, Utah State University, Logan, UT, USA.
Yang LiuDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Jennifer A DoudnaGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA, 94158.ORCID 0000-0001-9161-999X

Funding

Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
Resource Core II: In Vivo CoreU19NS132303 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI NIREN MURTHY · 2023 to 2026
$19.7M
Expanding CRISPR-Cas editing technology through exploration of novel Cas proteins and DNA repair systemsU01AI142817 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI BANFIELD, JILLIAN, DOUDNA, JENNIFER A · 2018 to 2022
$2.0M
Mapping the Cellular Responses to DNA Double-Strand Breaks Using On-Demand CRISPR technologies and High-resolution Fluorescence MicroscopyR35GM150941 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Yang Liu · 2023 to 2026
$1.7M
Cas9 RNP delivery to immune cells in vivo via molecular targetingUH3AI150552 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI DOUDNA, JENNIFER A, WILSON, ROSS C · 2022 to 2022
$1.3M
Targeted Delivery of Cas9 to Lung Epithelial Cells using Enveloped Delivery VehiclesR21HL173710 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI DOUDNA, JENNIFER A · 2024 to 2025
$520k
NHLBI NIH HHS R21 HL173710NIAID NIH HHS U01 AI142817NIAID NIH HHS U54 AI170792NIAID NIH HHS UH3 AI150552NIGMS NIH HHS R35 GM150941NINDS NIH HHS U19 NS132303
6 · The paper itself

Abstract

Genetic mutations that drive cancer often occur in tumor suppressor proteins, including the p53 transcription factor which is altered in ~40-50% of cases

Identifiers

PMID42146678
PMCPMC13174608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.